Patient engagement software and remote patient monitoring software have helped doctors considerably while treating patients. Along with these new innovations many companies are using other techniques to cure patients.

FDA has approved Teva Pharmaceuticals’ generic epinephrine auto-injector for the emergency treatment of allergic reactions including life-threatening ones. EpiPen will face competition from the generic version of the auto-injector marketed by Teva Pharmaceuticals, which is approved by the U.S. Food and Drug Administration.

Prior to this FDA had approved several epinephrine auto-injector products by EpiPen, Adrenaclick and Auvi-Q. Also, generic versions of EpiPen and Adrenaclick are marketed without brand names.

FDA said that this is the first approved generic version of EpiPen and EpiPen Jr.

Life-threatening allergies and anaphylaxis include reactions to insect bites or stings, medications, foods, latex or other causes. According to FDA, people who have suffered from an anaphylaxis episode should carry an emergency dose of epinephrine with them all the time as they face the risk of another episode.

FDA Commissioner Scott Gottlieb, MD said that the organization is committed towards the development of generic copies of complex products. He said that these products are tough to copy this, don’t face generic competition after the patents and exclusivity aren’t blocked for approval.